LV10231B - Novel 3,3-dithiobis (propionic acids) and esters thereof - Google Patents
Novel 3,3-dithiobis (propionic acids) and esters thereof Download PDFInfo
- Publication number
- LV10231B LV10231B LVP-93-822A LV930822A LV10231B LV 10231 B LV10231 B LV 10231B LV 930822 A LV930822 A LV 930822A LV 10231 B LV10231 B LV 10231B
- Authority
- LV
- Latvia
- Prior art keywords
- compound
- quot
- formula
- kurā
- cho
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C327/00—Thiocarboxylic acids
- C07C327/38—Amides of thiocarboxylic acids
- C07C327/40—Amides of thiocarboxylic acids having carbon atoms of thiocarboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
- C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
- C07C323/59—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton with acylated amino groups bound to the carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
- Liquid Crystal Substances (AREA)
Claims (9)
- LV 10231 Fatentformulas punkti 1. Savienojums ar kopējo formulu i S-CH-CH-SK-R » n S-CH-CH-SH -OC-R I C.oo£3 kurā: R - ūdeņradis vai -COR1, kur R1 - metilgrupa, etilgrupa, n-pro-pilgrupa, n-Putilgrupa, n-pentilgrupa, n-heksilgrupa, n-hep-tilgrupa, n-oktilgpupa, n-nonilgrupa, n-deoilgrupa, n-unde-oilgrupa, izopropilgpupa, 1-metilpropilgPupa, tero-butilgru-pa, 3-metilbutilgpupa, 2-metilbutilgpupa; 2 R - metilgrupa, c?υχx£i·upei 9 n*-yp«-»pj.j.&i*uyia 9 H—j^u.w.xgiTup*i 9 ir~pbii~ tilgrupa, n-heksilgrupa, n-heptilgrupa, n-oktilgpupa, n-nonilgrupa, n-deoilgpupa, n-undeoilgrupa, izopropilgpupa, 1 1- metilpropilgrupa, tero-butilgrupa, 3-metilbutilgrupa , 2- metilbutilgrupa; 3 R - ūdeņradis, metilgrupa, etilgrupa, n-propilgrupa, n-butil-grupa, izopropilgrupa, izobutilgrupa; ar noteikumu, ka R1 un R2 abi vienlaikus nav metilgrupa, kā arī ar *3 λ n noteikumu, ka, ja RJ ip ūdeņradis, tad R un Rc abi vienlaikus nav n-propilgrupa vai n-heptilgrupa, vai šo savienojumu fizioloģiski pieņemamās salis un / vai stereoiso-mēri.
- 2. Savienojums pēo punkta 1, kas atšķiras ar to, ka: R ir ūdeņradis vai -COR1, kur R1 ir metilgrupa, etilgrupa, n-propilgrupa, n-butilgrupa, n-pentilgrupa, n-heksilgrupa, n-heptilgrupa, n-oktilgrupa, n-nonilgrupa, n-deoilgrupa, n-undeoilgrupa, izopropilgrupa, 1-metilpropilgrupa, tero-butilgrupa, 3-metilbutilgrupa, 2-metilbutilgrupa; p R ir metilgrupa, etilgrupa, n—propilgrupa, n—butilgrupa, n-pentilgrupa, n-heksilgrupa, n-heptilgrupa, n-oktilgrupa, n-nonilgrupa, n-deoilgrupa, n-undeoilgrupa, izopropilgrupa, 1- metilpropilgrupa, tero-butilgrupa, 3-metilbutilgrupa, 2- metilbutilgrupa; R ir ūdeņradis, metilgrupa, etilgrupa, ar noteikumu, ka, ja R3 ir ūdeņradis, tad R1 un R2 abi vienlaikus nav n-propilgrupa vai n-heptilgrupa.
- 3. Savienojums pēo punkta 1, kas atšķiras ar to, ka 1 ° · . 3 T) ' n w T"3 ί m 4 ρτΛηηΑ^>4 1 i rsr% Va4· T3 * i v% ·? 1 r\ uū rx ii· izjUļjiupii&iupa , ι/ο o r\ 11· Ηΐσΐ4ΐΐ£,ΐΛΐ1ΛΛ. 2 LV 10231
- 4. Savienojums pēo punkta 1, kas atšķiras ar to, ka R1 un R2 ir n-pentilgrupa, iet R3 ir metilgrupa. 5. Savienojums peo punkta 1, kas atšķiras ar to, ka A ^ O R* nvļ T)t- 4 4 1 mm i V» rs4- Τ') ^ ņ y% rņr^4· T 1 1 u u h xF x*JuyFuyxxjK,iuy«a * £/σο λ χί* ηισ υχχ^Χ* up«a ·
- 6. Savienojums pēo punkta 1, kaB atšķiraB ar to, ka 1n t ny\ TlC· * v» #·«. V% * τηΛν<1 Αΐΐηιπ ι ιτλτν 1 mm i γ·λ ί *1 ίΐΓΐβ^ΓϊϋίΓι'ΙΟ n ua λ χα* «axxi vxciix<axivuo x*AJpi*upxx£,4 up<a j χ/συ r\ xi uu^iai <a*xx© · Savienojums peo punkta 1, kas atšķiras ar to, ka * η T . — # Π I pC» 4 v* r*. V * ντί fs^ln > n 4 av«a V> 1 vl· * 1 wi w i»srv V»m4 Ώ" i ** ίι A vio ^ i < Λ 1X44 Λ X4 ' «flXU V XC14Xdl J\ UO 004*U""X4U lfXX&i·LIJJtfl , JLK3fc XX XI* UUC^U'flUAO
- 8. Paņēmiens savienojuma ar kopējo formulu (I) pēo punkta 1 iegūšanai, kas atšķiras ar to, ka: a) oksidē N-aoiloisteīna atvasinājumu ar formulu: HS-CHn-CK-KH-OC-R1 c I C.00 R i a *3 *3 kurā R un R nozīmes ir jau minētās, un kad RJ ir ūdeņradis, iespējami šī savienojuma vieno jumu ar formulu: C-oon ' 1 c nu nu vu m_n I ij—uiin“vu— S-CHn-CH-KH-CO-R1 salis ar sārmu metālu, veidojot sa- c. tCOZ-ļ 3 b) apstrādā piemērotas bāzes klātienē savienojumu COO/J 3 * - o_mi nu itu ηπ η I ο—uiio η 1 c nu nu utu nn n t , tooz5 TTJif f 5 ļ'ļ ļ *** Ϊ^ΛΓ' nmA ί ** *r\ 11 ml v\ λ+ λ η v» £?γ»ττ4λιλα vcu v»d d<ui ixu.i4 rv xxwz»xuic xx* j<au ιιιχχχουο, <αι οαvxoxxV'/lu<iu π1 Μ fļfļY l/ļ ļ ļļ T?1 ļ*» mii m' v> η<4·Λ ΚλΧ HftV «ΛΛ (Vn+rtnn ίτ" mn Λ - OUA, XVUX- Λ XX* jau Uixxxcoaxo9 XJO\j ΆίΛ — l'Cd&C oopcj X&d grupa, kas spēj reaģēt ar aminogrupu dodot amīda grupu un veido savienojumu ar formulu <200 £* « 1 c nu nu vu nn ή * oe“wxxo”,^xxextxx*"'-/VA • c 1 o nu nu iru nn η I o’~ouo~t/ii~xixx*-L/v/"*x\ " ι ¢00¾ ο) 2-(K-aoilamino )-3-halogēnpropionskābes atvasinājumu CO0&3 ' . v nu nu *tu r\nn I x—οΠο^^χι—ΧΗιΐι—υοΛ c, kurā E1 nozīme ir jau minētā, E3’ir E3, kura nozīme ir jau minētā, vai labilu skābu vai bāzisku organisku grupu un Y ir halogēna atoms, apstrādā ar sēru vai disulfīda anjonu bāzes klātienē, veidojot savienojumu coofta I c nu nu vtu nn rj1 0 -uxio-wi~mi_uu“n 1 <=. c nu nu it u nn r> C l Coo £ 4 1 LV 10231 d) oksidē N-aoiloisteīna estera atvasinājumu maisījumu ar formulāmtOOd 3 H o nu nu utu nn u—ui i nuu“m iuu— n c π», η o nu nu uti nn nč-uu rl u—uun“uu—uu—υυ~η Ci90 β.3 1 P τ τ xdr R , R un R nozīmes ir jau minētās, vai, ja R ir ūdeņradis, vēlamB to sārmu metālu veidā, veidojot savienojumu ar formulu ftOOlU I Ο-UUO""UU* * I iru nn «1 mi *υυ· I\ rru nn n2 tOOii e) oksidē oisteīna vai oisteīna estera maisījumu ar N-aoiloiste-īna atvasinājumu ar formulu tOO&j, \ HS-CHo-CH-SH, C. i vai šī savienojuma sāli un uo nu nu utu nn τι i ιω-υιΐο-υιι-«ιι-υυ“Λ c. I CūOR.3 vai šī savienojuma sārmu metāla sālis vai šī savienojuma sāl- rtVRVRn η η 1 " n 1m η ι iv» Tļ3 m/srr? mrtrt i « m* «SiRrl rrm A Λ («ļ' nix&u<no oeaxxo, aui· n uu r\ uu2>.uuuo u· j<au iuuxeoiio, vexuuJuo savienojumu ar formulu C00£3 i S-OH^-CH-KHoV c " 1 o nu nu utu nn_n i u—uuo—uu—uu—uu—λ £ \ toon3 vai tā sāli, 5 Γ) apstrādā piemērotas bāzes klātienē cisteīna vai oisteīna di estera, vai šī diestera sāls pārākumu ar formulu COOČi 1 S-CH0-CH-KHn , c c S-CHn-CH-HHn €0 Οβ?, kur R3 ir jau minētā nozīme, ar savienojumu R2-COX, kur R2 un COX nozīmes ir jau minētās, veidojot savienojumu ar formu lu: S-CHn-CH-KH, I c nu nu itu nn_nt o"uio-ui*mnArn č. g) piemērotas bāzes klātienē apstrādā savienojumuar formulu 1 tOOHi I S-CHn-CK-NH-OO-R I " S-CHn-CH-KHo I C.O0&1 vai tā sali, kur R1 un R3 ir jau minētās nozīmes, ar savienojumu R2-C0X, kur R2 un COX nozīmes ir jau minētās, veidojot savienojumu ar formulu &)0(i 3 1 i c* nrr nti iru nn n O—OUn—'-'AA AtlA—uu—Λ « A 2 S-CHo-CK-KH-OC-R & too^ 6 LV 10231 h) apstrādā K-atviloisteīna atvasinājumu ar formulu 100 L· \ ES-CHn-CK-KK-OC-R c. rrn * 4S r»S1 i vaa o<a oauMf 1 -5 R un RJ nozīmes ir jau minētās, ar akti vē jošu reaģentu, kas veido adduktu ar formulu: \ it ο ητι ηττ ιτττ nn n uu-mr ιλτ λ I cλ/Η -cooc^Hs* 1 un pēo tam apstrādā ar otru, atšķirīgu no pirmā, vai tādu pašu N-aoiloisteīna atvasinājumu vai oisteīna esteri, veidojot ηΐΝττι AVin μι ^λ»ι»»»ι i 1 i i o3 v juuujujhu cai* iOPmuiu CjOO&i 1 ipu _ntr ira nn rj iJ Ulri-Ul-flirU'J-ft cj_nu J'n nn r)£ *j ui2 i/u-ftu-wn 1 OOO&I i) apstrādā savienojumu ar formulu R4-S-CHn-CH-ī«ī-0C-R1 T)^" 4n j\lu <a η χι- 0 U αοοβ·^ -R1 /° Tff\ *t VtfU. - N X0 1 •ļrn 4 _q nu nu nu ηη_τι vai o—oii-wu_n ii c 0 J kur R^ un Rv’ nozīmes ir jau minētās, ar savienojumu, kura formula ir 0,001$* * uc nu m.iru nn nc uo"~uuo λΠ—vvr-rv p TT l/11 «ζ TW tnnnnvMr.m ·* V% {<m, iviiu»R4s« « — _i_ i · · acu a n un. n i4>-/^xmoo xi· jaU minētas, iegūstot savienojumu 7 ar formulu t00&2> v nu nu itu nn rj1 u~uurr-uii—mi-υο—K S-CHo-CH-KH-OC-Rc too c i Kura, ja nepieciešams iegūt savienojumu ar RJ = H, aizvāc aiz-sarggrupu , j) esterifioē savienojumu ar formulu tox1 I c? nu rvti iru u~Vj»u^“oii*~xux t 41 0 nu nti tTU o~vxxo~ *uxx-“x\xi c <2θΧ x\ 1 /·ι i nr% T) JVLirS K Uil K*~ nnsnrr.pc: 1 Γ* 121 ļ m*r»"+or* V* * r» nu nmi 1 ττ«-ν i 1nr· ļ Λ χνίΛΑ c* Π LUl n. XX*J4/XIIICw Ai ļjau.-ilU4J.c;ti<ftOy Λ li' \Jii £,X‘LiļJtft ΥΛΑ «ēna atoms ar* savi00.0inmu u^Enu twS ;n e,cu<a ai oav icnu jumu r\ v/11, n.ux-a r\ xi- ιΐι6υιΐ£,ι*ιχμα, etilgrupa, n-propilgrupa, n-butilgrupa, izopropilgrupā, izobutilgrupa, veidojot savienojumu ar formulu tOO(LZB l . S-CHo-CH-KH-OO-R 1 C o S-CHo-CK-Kii-00-Ru tOoH k) alkilē savienojumu ar formulu QjQO P° i S-CHo-CH-KH-0C-R \ * o S-.f’H _™_wu nn t>£ *-> '-Ήη-ωι-ϋπ-υυ-η Coo ^ kurā R un Rc ir jau minētās nozīmes, ar savienojumu R3E-Z, w Vļļļ^ 007T !J1P "ī ΤΪ *IM1 m* Vi r^l f7 * V* Unl η »»Λνιη nlVilnilIfRlrt λιλι n. iiux<i 111c n· uuucoa, ikju u 11· iiaiuguiio, aifuiounabo 8 LV 10231 tozilāts vai jebkurš cits viegli atšķeļams aromātisko oiklu saturošs atlikums, veidojot savienojumu ar formulu ¢,00/2 / . S-CHo-CH-KH-00-R I c’ nu nu \tu nn r>c. c. , t p 1) piemērotas bāzes klātienē apstrādā karboksilaizvietota oistī-na atvasinājumu ar formulu QjQ0i \ 1P .S-CHn-CH-KHn l c o_ pu puitu ϋ"υυο nju-imo c I teo R -ļP nņ ττηί 4n pini n1rnV\A ņR1* 1μιλ T1^* . 1 aV>*1 λ rilrnt>r 4 VRrri a»i . ναι ua ολχολοαλλ ©αχχ * ituP x\ αχ* χαι/χχα οιχαι/α ναχ .υα^χοΛα Qr— 1 1 ganiska grupa, ar savienojumu R -C0X, kur R ir jau minētā nozīme, bet C0X ir reagētspējīga grupa, kas ar aminogrupu spēj — 'ļp veidot amīda grupu, peo tam aizvācot aizsarggrupu R un veidojot savienojumu ar formulu cto o& c nu nu wu nn π l • ϋ"υι in“ uu""uu“* n < * 1 o nu nu \tu nn tī » ū“uin*"'jU""iin""VA»,*n c ( tocd m) sārmainā vidē apstrādā karboksilaizsargātu cietina atvasinājumu ar formulu c-ood %p S-CHo-CH-HHo © c.' I S-CHo-CH-NHo »ιγμ X ņ nr%1 nnl i Ifim Γ3 MAPrTmn ί n * v> rv v» pidtt* λ v«ax Ud οΛΧΟΛΛ^υ o«axif i\ur r\ h»j*ixmic? xr jau uixu6waf ar oavicr 9 ii'jju.inu R -COX, kura R un GOX nozīmes ir* jau minētas , talak 30Š4.84.C0 aizsrggrupu R un iegūstot savienojumu ar formulutcoH iS-CHo-CR-HH2 c I S-CH^-CH-ltK-OC-Rc c f to oH n) apstrādā karboksiaizsargāta oistīna atvasinājumu ar formulu (LOOii 3 P S-CHo-CH-NHo, ^ «1 o o nu nu \ru nn rjt υυ- λ c t ^ . 0 TP TT2iT 4¾ CGI JJf^l 1 ļ.r1 1 13^ ļ 1 T) "i* vt/\rv?»wnn * v» 'nu «v> * v> r>A nn VdA t»«a DdADAdiJV odilp JVCU* I\ LU.1 x\ ilVftXUICO Ai* |ļdU UIAllUUdO) 1 - 1 _ j ., .. , r;- - ?ΤΤί3 Ϊ I? ΡΠΥ 1/Ί 1 y*<5 D nv» ππν v%/%rp 1 w>nn ίηη *·λ? %»» P1. A rk #-1 di Od VACUJX\J UIIIU A *WAj AUl'd A UAi UVA iiVZiJ.lUOO XI* JdtLl lltAiiUOdOf « /sr» λ · γϊτι rpvti 1 t*.ļ ļ T3 vf 1 Klr λ + ΧΤρλ‘1 λ4> ....... UdAclA A un veidojot savienojumu tooff 1 S-CHo-CK-RH-OC-R o nti nu vtj nn >j—'-'Ai—iUU —«JUTI C00H Λ ί ηΙλ " V% υιο ociiid 0) iestādot sārmainā ūdens šķīdumā līdzsvaru starp oistīna un atvaisinājumiem ar formulām tOOH S-CHo-CH-KK-OC-R1 u_nu _nu iTti nn r>1 u~uur> 'Jii—mi-vjo—rv <U>OH LeoHU un, attiecīgi UO.PIJ nu itu nn ne c ♦ 1 n tā sārmu sāļiem, kur R un R* ir jau minētās nozīmes, veido jo 10 LV 10231 savienojumu ar formulu (tOOK e nu nu wu nn n · ū-wļo_wi~iui_uv/~n 1 C P o nu nu itu nn rjc. c. (UlOH un, beidzot, ja vajadzīgs, pārvērš pēo jebkura no paņēmieniem a) - o) iegūtos savienojumus, par to fizioloģiski pieņemamām sālīm. 9. Ārstniecības līdzeklis, kas atšķiras ar to, ka tajā kā aktīvā viela iekļauts savienojums pēo jebkura no punktiem 1-17. 10. Ārstniecības līdzeklis pēo punkta 9 gatavā zāļu formā. 11. Ārstnieoības līdzeklis pēo punkta 9 un 10, kas atšķiras ar to, ka aktīvā viela tajā iekļauta kopā ar farmaceitiski pieņemamu nesēju.
- 12. Savienojuma pēo jebkura no punktiem 1 - 7 pielietojums par terapeitiski aktīvu vielu.
- 13. Paņēmiens imūnomodulējoši darbīgu zāļu gatavo formu iegūšanai, kas atšķiras ar to, ka izmanto savienojumus pēo jebkura no punktiem 1-7. 11
- 14. Paņēmiens tādu slimību ārstēšanai, kuras izsauc zīdītāju, ieskaitot cilvēku, imūnās sistēmas darbības trauoējumi, kas atšķiras ar to, ka ārstējamā organismā ievada efektīvu daudzumu savienojuma pēc šī izgudrojuma punktiem 1-7. 12
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9002275A SE9002275D0 (sv) | 1990-06-28 | 1990-06-28 | Novel 3,3'-dithiobis(propionic acids) |
| SE9002274A SE9002274D0 (sv) | 1990-06-28 | 1990-06-28 | Novel 3,3'-dithiobis(propionic esters). |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| LV10231A LV10231A (lv) | 1994-10-20 |
| LV10231B true LV10231B (en) | 1995-04-20 |
Family
ID=26660808
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LVP-93-822A LV10231B (en) | 1990-06-28 | 1993-06-30 | Novel 3,3-dithiobis (propionic acids) and esters thereof |
Country Status (31)
| Country | Link |
|---|---|
| EP (1) | EP0463514B1 (lv) |
| JP (1) | JPH04230359A (lv) |
| KR (1) | KR920000714A (lv) |
| CN (1) | CN1039318C (lv) |
| AT (1) | ATE120730T1 (lv) |
| AU (1) | AU642259B2 (lv) |
| CA (1) | CA2045289A1 (lv) |
| CZ (1) | CZ279343B6 (lv) |
| DE (1) | DE69108616T2 (lv) |
| DK (1) | DK0463514T3 (lv) |
| EG (1) | EG20191A (lv) |
| ES (1) | ES2070370T3 (lv) |
| FI (1) | FI913131A (lv) |
| HK (1) | HK62397A (lv) |
| HR (1) | HRP920766A2 (lv) |
| HU (1) | HU210675B (lv) |
| IE (1) | IE71024B1 (lv) |
| IL (1) | IL98389A (lv) |
| IS (1) | IS1697B (lv) |
| JO (1) | JO1677B1 (lv) |
| LV (1) | LV10231B (lv) |
| NO (1) | NO175307C (lv) |
| NZ (1) | NZ238495A (lv) |
| PH (1) | PH30951A (lv) |
| PL (2) | PL165344B1 (lv) |
| PT (1) | PT98121B (lv) |
| RU (1) | RU2041208C1 (lv) |
| SI (1) | SI9111086A (lv) |
| SK (1) | SK278710B6 (lv) |
| TW (1) | TW221376B (lv) |
| YU (1) | YU48643B (lv) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9103572D0 (sv) * | 1991-11-29 | 1991-11-29 | Astra Ab | Organic salts of n,n'-diacetyl cystine |
| SE9500897D0 (sv) * | 1995-03-14 | 1995-03-14 | Astra Ab | The pharmacological use of certain cystine derivatives |
| CN100453531C (zh) * | 1998-10-09 | 2009-01-21 | 味之素株式会社 | 半胱氨酸衍生物 |
| SE9900438D0 (sv) * | 1999-02-10 | 1999-02-10 | Astra Ab | The pharmacological use of certian cystine derivatives |
| US8295265B2 (en) | 2005-11-16 | 2012-10-23 | Htc Corporation | Method for handling radio bearer messages during reset and reestablishment in a wireless system |
| US7829709B1 (en) | 2007-08-10 | 2010-11-09 | Marquette University | Cysteine prodrugs to treat schizophrenia and drug addiction |
| ES2613729T3 (es) | 2008-02-07 | 2017-05-25 | Marquette University | Cisteína y profármacos de cisteína para tratar la esquizofrenia y reducir los deseos compulsivos por los fármacos |
| CN103319388B (zh) * | 2013-06-08 | 2014-11-05 | 西安交通大学 | 一种双功能聚乙二醇衍生物及其制备方法 |
| WO2015163488A1 (en) * | 2014-04-25 | 2015-10-29 | Ajinomoto Co., Inc. | Immunostimulating agent |
| WO2017073797A1 (en) | 2015-10-28 | 2017-05-04 | Ajinomoto Co., Inc. | Immunostimulating agent |
| EP3395365A1 (en) | 2017-04-28 | 2018-10-31 | Ajinomoto Co., Inc. | Immunostimulating agent |
| CN111072537B (zh) * | 2019-12-20 | 2021-11-19 | 南京德尔诺医药科技有限公司 | 一种双乙酰化-l-胱氨酸的制备方法及其应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR8205M (lv) * | 1968-12-20 | 1970-09-14 | ||
| US3878305A (en) * | 1972-05-25 | 1975-04-15 | Procter & Gamble | Fortification of foodstuffs with n-acyl derivatives of sulphur-containing l-amino acids |
| US3952115A (en) * | 1975-04-02 | 1976-04-20 | The Procter & Gamble Company | Fortification of foodstuffs with N-acyl derivatives of sulfur-containing L-amino acid esters |
| FR2503151A1 (fr) * | 1981-04-02 | 1982-10-08 | Morelle Jean | Butyryminoacides soufres. mode de preparation. emploi comme element keratogenique chez l'homme et l'animal et comme agent de fertilisation chez les vegetaux |
| US4724239A (en) * | 1985-09-16 | 1988-02-09 | Morgan Lee R | Method of treating chemical ulcers with N,N'-diacetylcystine, N-acetyl homocysteine and N-acetyl cysteine |
| US4827016A (en) * | 1985-09-16 | 1989-05-02 | Morgan Lee R | Method and compounds for reducing dermal inflammations |
| US4708965A (en) * | 1985-09-16 | 1987-11-24 | Morgan Lee R | Method of treating herpes virus infections with N,N'-diacetylcystine and derivatives |
| JPS62195356A (ja) * | 1986-02-20 | 1987-08-28 | Seiwa Kasei:Kk | シスチン誘導体及びその塩 |
-
1991
- 1991-05-28 TW TW080104179A patent/TW221376B/zh active
- 1991-06-05 IL IL98389A patent/IL98389A/xx not_active IP Right Cessation
- 1991-06-11 NZ NZ238495A patent/NZ238495A/en not_active IP Right Cessation
- 1991-06-11 AU AU78284/91A patent/AU642259B2/en not_active Ceased
- 1991-06-14 ES ES91109808T patent/ES2070370T3/es not_active Expired - Lifetime
- 1991-06-14 AT AT91109808T patent/ATE120730T1/de not_active IP Right Cessation
- 1991-06-14 DE DE69108616T patent/DE69108616T2/de not_active Expired - Fee Related
- 1991-06-14 EP EP91109808A patent/EP0463514B1/en not_active Expired - Lifetime
- 1991-06-14 DK DK91109808.5T patent/DK0463514T3/da active
- 1991-06-19 YU YU108691A patent/YU48643B/sh unknown
- 1991-06-19 SI SI9111086A patent/SI9111086A/sl unknown
- 1991-06-20 EG EG38991A patent/EG20191A/xx active
- 1991-06-24 CA CA002045289A patent/CA2045289A1/en not_active Abandoned
- 1991-06-25 PH PH42684A patent/PH30951A/en unknown
- 1991-06-26 IE IE222391A patent/IE71024B1/en not_active IP Right Cessation
- 1991-06-27 NO NO912545A patent/NO175307C/no not_active IP Right Cessation
- 1991-06-27 RU SU914895759A patent/RU2041208C1/ru not_active IP Right Cessation
- 1991-06-27 PT PT98121A patent/PT98121B/pt active IP Right Grant
- 1991-06-27 HU HU912169A patent/HU210675B/hu not_active IP Right Cessation
- 1991-06-27 JP JP3181592A patent/JPH04230359A/ja active Pending
- 1991-06-27 FI FI913131A patent/FI913131A/fi unknown
- 1991-06-27 JO JO19911677A patent/JO1677B1/en active
- 1991-06-27 KR KR1019910010793A patent/KR920000714A/ko not_active Application Discontinuation
- 1991-06-28 IS IS3728A patent/IS1697B/is unknown
- 1991-06-28 SK SK1990-91A patent/SK278710B6/sk unknown
- 1991-06-28 PL PL91290857A patent/PL165344B1/pl not_active IP Right Cessation
- 1991-06-28 CN CN91104324A patent/CN1039318C/zh not_active Expired - Fee Related
- 1991-06-28 PL PL91293118A patent/PL165349B1/pl not_active IP Right Cessation
- 1991-06-28 CZ CS911990A patent/CZ279343B6/cs unknown
-
1992
- 1992-10-01 HR HRP-1086/91A patent/HRP920766A2/xx not_active Application Discontinuation
-
1993
- 1993-06-30 LV LVP-93-822A patent/LV10231B/en unknown
-
1997
- 1997-05-08 HK HK62397A patent/HK62397A/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AP1204A (en) | Nitric oxide synthase inhibitors. | |
| EP0765308B1 (en) | Enzyme inhibitors | |
| CA1273019A (en) | Enkephalinase inhibitors | |
| US5473100A (en) | Hydroxamic acid derivative | |
| LV10231B (en) | Novel 3,3-dithiobis (propionic acids) and esters thereof | |
| US5350767A (en) | Derivatives of cysteine | |
| US5889050A (en) | 3,3'-dithiobis (propionic acids) and esters thereof | |
| EP0515995A2 (en) | N-(5-thioxo-L-prolyl)-L-cysteine, derivatives thereof, processes for the preparation thereof and pharmaceutical compositions containing them | |
| US6620848B2 (en) | Nitric oxide synthase inhibitors | |
| LT3976B (en) | Novel 3,3'-dithiobis(propionic acids) and esthers thereof | |
| EP0356137B1 (en) | Carbonates of 3-demethylthiocolchicine and N-acyl analogs | |
| AU747551B2 (en) | New compounds | |
| US6369272B1 (en) | Nitric oxide synthase inhibitors | |
| EP0408106B1 (en) | Novel acrylic amide derivatives, a process for their preparation, pharmaceutical compositions containing the same and their use in medicine | |
| MXPA99006172A (en) | Nitric oxide synthase inhibitors |